Portal Innovation's 30,000-square-foot Helix Park lab space is open for business. Photo via Portal Innovations/X

A new life science-focused venture capital engine has officially opened offices in Houston.

Portal Innovations moved into a space at Helix Park in October. The offices are led by executive director Monique Knighten.

Knighten has been in Houston for 16 years, since she was a postdoc at the University of Texas Institute for Molecular Medicine. “It's like a lot of us. We come for a specific reason, and then we just find reasons to stay,” she says.

And now, that reason is to push the emerging Houston ecosystem forward by helping early-stage startups to build themselves toward success. Portal does that partly by providing capital, but besides cash investments, emerging companies need a physical infrastructure where their work can happen. They also need great people to support their cause at every step of development. To that end, networking and convening with beneficial people is key for Portal.

With locations already in Chicago, Boston and Atlanta, why did Portal choose Houston?

“If you take a look at where lots of scientific publications are coming from, if you look at where a lot of technology that eventually becomes commercialized, a lot of it will come initially from labs that are right here in Houston,” says Knighten. “Houston also has a great quality of life. That's really important so that startups need to be able to have a place where they can have their teams.”

And who has joined Portal in its 30,000-square-foot Helix Park lab space? March Biosciences, a cancer-focused cell therapy startup; Crossbridge Bio, responsible for a cancer therapeutic that just closed a $10 million seed round; Artidis, which is personalizing cancer diagnosis thanks to a new nanomedical biomarker technology; Spanios, which has created human model systems to help researchers better identify therapeutic options for solid tumors; Stingray Therapeutics, a cancer immunotherapy company working on metastatic or advanced solid tumors; Remunity Therapeutics, an immuno-oncology startup developing immune-stimulating antibody-drug conjugates that reactivate anti-tumor immune response; and Phiogen, which is doing promising work in the world of non-antibiotic anti-infectives.

The Cancer Focus Fund, an oncology-focused investment fund in partnership with The University of Texas MD Anderson Cancer Center is also sharing space with the burgeoning biomedical companies.

Even Texas Medical Center CEO Bill McKeon is excited to greet Portal.

“In Portal, we have a partner with a proven track record of leveraging venture capital funding, expert partners and strong programming to support dynamic, entrepreneurial businesses at pivotal moments of their growth. We look forward to building on our collective expertise and shared vision to further support the breakthroughs of early-stage life science ventures,” he says on the company’s website.

By working with Portal, each of the companies will benefit not only from Knighten’s expertise i building teams gathered from her time at Sartorius Stedim Biotech and decade with Miltenyi Biotec, but also that of the other Portal teams. Working on a national scale also gives the brands opportunities for national exposure. Just one more way, Houston’s ecosystem is continuing to move the needle both for the healthcare companies in it and the patients who will one day benefit.

This week's roundup of Houston innovators includes Sean Kelly of Amperon, Amanda Burkhardt of Phiogen, and Mielad Ziaee of UH. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Sean Kelly, CEO and co-founder of Amperon

Amperon CEO Sean Kelly joins the Houston Innovators Podcast to share his company's growth and expansion plans. Photo via LinkedIn

The technology that Amperon provides its customers — a comprehensive, AI-backed data analytics platform — is majorly key to the energy industry and the transition of the sector. But CEO Sean Kelly says he doesn't run his business like an energy company.

Kelly explains on the Houston Innovators Podcast that he chooses to run Amperon as a tech company when it comes to hiring and scaling.

"There are a lot of energy companies that do tech — they'll hire a large IT department, they'll outsource a bunch of things, and they'll try to undergo a product themselves because they think it should be IP," he says on the show. "A tech company means that at your core, you're trying to build the best and brightest technology." Continue reading.

Amanda Burkhardt, CEO of Phiogen

Spun out of Baylor College of Medicine, Phiogen was selected out of 670 companies to pitch at SXSW earlier this month. Photo via LinkedIn

A new Houston biotech company won a special award at the 16th Annual SXSW Pitch Award Ceremony earlier this month.

Phiogen, one of 45 companies that competed in nine categories, was the winner for best inclusivity, much to the surprise of the company’s CEO, Amanda Burkhardt.

Burkhardt tells InnovationMap that while she wanted to represent the heavily female patient population that Phiogen seeks to treat, really she just hires the most skilled scientists.

“The best talent was the folks that we have and it ends up being we have three green card holders on our team. As far as ethnicities, we have on our team we have Indian, African-American, Korean, Chinese Pakistani, Moroccan and Hispanic people and that just kind of just makes up the people who helped us on a day-to-day basis,” she explains. Continue reading.

Mielad Ziaee, 2023-2024 All of Us Research Scholar

Mielad Ziaee, a 20-year-old student at the University of Houston, was tapped for a unique National Institutes of Health program. Photo via UH.edu

A Houston-area undergraduate student has been tapped for a prestigious national program that pairs early-career investigators with health research professionals.

Mielad Ziaee was selected for the National Institutes of Health’s 2023-2024 All of Us Research Scholar Program, which connects young innovators with experts "working to advance the field of precision medicine," according to a statement from UH. Ziaee – a 20-year-old majoring in psychology and minoring in biology, medicine and society who plans to graduate in 2025 — plans to research how genomics, or the studying of a person's DNA, can be used to impact health.

“I’ll be one of the ones that define what this field of personalized, precision medicine will look like in the future,” Ziaee said in a statement. “It’s exciting and it’s a big responsibility that will involve engaging diverse populations and stakeholders from different systems – from researchers to health care providers to policymakers.” Continue reading.

Spun out of Baylor College of Medicine, Phiogen was selected out of 670 companies to pitch at SXSW earlier this month. Photo via Getty Images

Houston startup recognized for inclusivity on journey to commercialize next-gen therapeutics

future of medicine

A new Houston biotech company won a special award at the 16th Annual SXSW Pitch Award Ceremony earlier this month.

Phiogen, one of 45 companies that competed in nine categories, was the winner for best inclusivity, much to the surprise of the company’s CEO, Amanda Burkhardt.

Burkhardt tells InnovationMap that while she wanted to represent the heavily female patient population that Phiogen seeks to treat, really she just hires the most skilled scientists.

“The best talent was the folks that we have and it ends up being we have three green card holders on our team. As far as ethnicities, we have on our team we have Indian, African-American, Korean, Chinese Pakistani, Moroccan and Hispanic people and that just kind of just makes up the people who helped us on a day-to-day basis,” she explains.

Phiogen was selected out of 670 companies to be in the health and nutrition category at SXSW.

“We did really well, but there was another company that also did really well. And so we were not selected for the pitch competition, which we were a little bummed about because I killed the pitch,” Burkhardt recalls.

But Phiogen is worthy of note, pitch competition or not. The new company spun off from research at Dr. Anthony Maresso’s TAILOR Labs, a personalized phage therapy center at Baylor College of Medicine, last June.

“Our whole goal is to create the next generation of anti-infectives,” says Burkhardt.

That means that the company is making alternatives to antibiotics, but as Burkhardt says, “We’re hoping to be better than antibiotics.”

How does it work? Bacteriophages are viruses that infect bacteria.

“You can imagine them as the predators in the bacteria world, but they don't infect humans. They don't affect animals. They only infect bacteria,” Burkhardt explains.

Phiogen utilizes carefully honed bacteriophages to attack bacteria that include the baddies behind urinary tract infection (UTI), bacteremia (bacteria in the blood), and skin wounds.

The team’s primary focus is on treatment-resistant UTI. One example was a male patient who received Phiogen’s treatment thanks to an emergency-use authorization from the FDA. The gentleman had been suffering from an infection for 20 years. He was treated with Phiogen’s bacteriophage therapy for two weeks and completely cleared his infection with no recurrence.

Amanda Burkhardt is the CEO of Phiogen. Photo via LinkedIn

But Phiogen has its sights set well beyond the first maladies it’s treated. An oft-quoted 2016 report projected that by 2050, 10 million people a year will be dying from drug-resistant infections.

“A lot of scientists call it the silent pandemic because it's happening now, we're living in it, but there's just not as much being said about it because it normally happens to people who are already in the hospital for something else, or it's a comorbidity, but that's not always the case, especially when we're talking about urinary tract infections,” says Burkhardt.

Bacteriophages are important because they can be quickly trained to fight against resistant strains, whereas it takes years and millions of dollars to develop new antibiotics. There are 13 clinical trials that are currently taking place for bacteriophage therapy. Burkhardt estimates that the treatment method will likely gain FDA approval in the next five years.

“The FDA actually has been super flexible on progressing forward. Because they are naturally occurring, there's not really a safety risk with these products,” she says.

And Burkhardt, whose background is in life-science commercialization, says there’s no better place to build Phiogen than in Houston.

“You have Boston, you have the Bay [Area], and you have the Gulf Coast,” she says. “And Houston is cheaper, the people are friendlier, and it’s not a bad place to be in the winter.”

She also mentions the impressive shadow that Helix Park will cast over the ecosystem. Phiogen will move later this year to the new campus — one of the labs selected to join Baylor College of Medicine.

And as for that prize, chances are, it won’t be Phiogen’s last.

PHIOGEN, based at Texas Medical Center Innovation, is headed to Austin next month. Photo courtesy of TMC

Houston biotech startup selected to pitch at SXSW

austin bound

Houston biotech startup PHIOGEN is among 45 finalists that will present at this year’s SXSW Pitch showcase in Austin.

PHIOGEN is one of five food, nutrition, and health startups that will participate in the pitch competition, set for March 9 and 10. A panel of judges will listen to the pitches and then pick the winners. Since 2009, SXSW Pitch finalists have raised more than $23.2 billion in funding.

PHIOGEN has developed the world’s first biogenetics technology platform to harness the power of bacteriophages in the fight against serious drug-resistant infections. Bacteriophages — viruses that are found in bacterial cells — “are ubiquitous in the environment and are recognized as the most abundant biological agent on earth,” according to an article published in 2022 by StatPearls.

Founded in 2023, PHIOGEN is a spinoff of the Baylor College of Medicine’s TAILOR Labs. The startup, based at the Texas Medical Center’s Innovation Hub, has attracted more than $5 million in funding.

“Nothing about our treatments is fabricated; it boils down to creating natural environments that mimic real-life infections, driving biological changes to create ‘super phages’ against the superbugs,” Amanda Burkardt, CEO of PHIOGEN, said in 2023. “As a result, we receive high-performing phage fighters that are trained and ready to deliver safe and effective treatments for clinical applications.”

Professional services firm KPMG is the main sponsor of SXSW Pitch.

Six of this year’s SXSW Pitch judges are from Houston:

  • Heath Butler of Mercury Fund
  • Jesse Martinez of LSA Global
  • Trevor Purvis of the Houston Astros
  • Anu Puvvada of KPMG
  • Irene Tang of StartOut
  • Nate Thompson of HTX Sports Tech

“2024 is an exciting year for startups, and we are looking forward to showcasing these inspiring companies that are making waves in their respective industries and the world as a whole, as well as help connect them with the resources needed to continue advancing,” says Chris Valentine, producer of SXSW Pitch.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

2 Houston suburbs rank among 10 best cities to retire, says U.S. News

Slowing Down

Houston and nine of its suburbs are earning new acclaim on U.S. News and World Report's just-released list of the best U.S. cities for retirees in 2027. Two northern suburbs, The Woodlands and Spring, are resting easy among the top five nationwide.

The 2027 Best Places to Retire list evaluated over 850 U.S. cities based on six livability metrics that best serve American retirees: quality of life, affordability, health care, retiree taxes, job market, and population and migration. The top 250 finalist cities were then ranked nationally and by city size.

Midland, Michigan topped the list for the second consecutive year and is followed by Homosassa Springs, Florida (No. 2) and Weirton, West Virginia (No. 3).

The Woodlands and Spring respectively maintained their standings as the No. 4 and No. 5 best cities for retirees for the second year in a row. The Woodlands topped the separate list of the best midsized U.S. cities to retire, while Spring landed 5th among the smallest U.S. cities.

Houston proper was declared the No. 2 best big city for retirees, and it ranked 89th overall. Elsewhere in the metro, Pearland (No. 13) and Conroe (No. 14) ranked just outside the overall top 10 but ranked 4th and 5th among the best midsized cities for retirees.

U.S. News said affordability is the "most considered factor" when it comes to picking the best place to live a low-stress retirement life, and that's what Houston and its neighbors deliver. Affordable cities also give retirees "a sense of security and comfort as they live out their golden years," according to Megan Wood, U.S. News assistant managing editor of home services and real estate.

"It’s no secret that affordability is top of mind for Americans this year, which is why U.S. News updated its weighting criteria to better align with what retirees prioritize," Wood said. "The 2027 rankings reflect key metrics used to highlight the places that
best suit retiree needs."

Sugar Land was declared the 10th best place to live in the U.S. in a separate U.S. News report earlier this year, but it doesn't quite meet the expectations for retirees. This particular suburb ranked as the 45th best overall city to retire, but it fared better in the city size ranking and landed 13th among the biggest U.S. cities.

Pasadena also surprised as the 85th best place to retire nationwide in this report, despite being hailed as the No. 3 best city to retire in Texas by RetirementLiving.com.

Three more Houston neighbors ranked among the top 100 overall best places to retire for 2027: League City (No. 25), Missouri City (No. 49), and Baytown (No. 88).

These are the top 10 best U.S. cities to retire for 2027:

  • No. 1 – Midland, Michigan
  • No. 2 – Homosassa Springs, Florida
  • No. 3 – Weirton, West Virginia
  • No. 4 – The Woodlands
  • No. 5 – Spring, Texas
  • No. 6 – Rio Rancho, New Mexico
  • No. 7 – Altoona, Pennsylvania
  • No. 8 – Paducah, Kentucky
  • No. 9 – Lynchburg, Virginia
  • No. 10 – Palm Coast, Florida
---

This article first appeared on CultureMap.com.

Air taxi network to land in 'Texas triangle' of Houston, Austin, DFW next year

taking flight

San Jose, California-based aerospace company Archer Aviation is bringing its air-taxi system to the “Texas triangle” of Houston, Austin and Dallas-Fort Worth.

Currently, the planned zero-emission electric air taxi networks will use Archer’s Midnight air taxi to “turn 60- to 90-minute drives to major airports, business districts and major destinations into 10- to 20-minute flights,” the company said in a news release. Archer plans to begin flights in the Texas triangle next year.

The Midnight air taxi is an all-electric vertical takeoff and landing (eVTOL) aircraft. It can carry four passengers and a pilot and is designed for consecutive flights of about 20 miles.

Archer cites the Texas triangle as one of the busiest and fastest-growing “megaregions” in the country due to its proximity to coastal regions, major airports, and a number of business districts.

Archer Chief Commercial Officer Nikhil Goel described the air taxi experience to CW Houston as “100 times quieter than a helicopter for the price of an Uber Black.” He added that the air taxis are a combination of a helicopter, a small airplane and a drone.

In Houston, Archer’s air taxi network will aim to connect George Bush Intercontinental, William P. Hobby and Sugar Land Regional Airport with downtown destinations, including the Thompson Hotel helipad, and Galveston.

In Austin, it plans to link the city's Austin-Bergstrom International Airport and Austin Executive Airport with the F1 Circuit Helipad at the Circuit of the Americas. Archer debuted its Midnight aircraft at the F1 Prix in the Fan Zone and the F1 Paddock at Austin’s Circuit of the Americas. The Dallas-Fort Worth network is slated to include Dallas-Fort Worth International Airport, Dallas Love Field, Addison Airport, Arlington Municipal Airport, Fort Worth Meacham International Airport and Perot Field Fort Worth Alliance Airport, plus major business hubs like Frisco Station.

“Texas is setting the bar for America’s leadership in the next generation of aviation,” Adam Goldstein, founder and CEO of Archer Aviation, said in the release. “Our planned networks will make the benefits of electric air taxis real for Texans — trading hours in traffic for minutes in the air, while connecting the biggest airports, business districts and sporting hubs in ways that America’s largest megaregion needs to grow.”

Archer is working with state and local partners to develop charging infrastructure and plans to pursue Texas operations through the White House’s eVTOL Integration Pilot Program, according to the release. It recently completed its "No Roads" flight tour, which included multiple flights over the San Francisco Bay, and flew to seven cities over three days.

5 Houston deep tech startups pushing the boundaries of their industries

meet the finalists

Houston has long been at the forefront of innovation, from NASA’s Johnson Space Center to its startup ecosystem using technology to disrupt industries.

As part of the 2026 Houston Innovation Awards, our Deep Tech Business category will honor an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors.

Five deep tech companies have been named finalists for the 2026 award.

Read more about these businesses, their founders and their breakthrough technologies below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Casimir

Battery tech startup Casimir develops semiconductor chips that produce continuous electrical power straight from the quantum vacuum, without the need for a battery, cord or external charge source. The company is targeting commercialization for its first-generation MicroSparc chip by 2028.

Harold “Sonny” White founded Casimir in 2023 after nearly two decades at NASA. The company emerged from stealth with a $12 million seed round in 2026. It was also awarded an STTR Phase I contract from the U.S. Space Force's SpaceWERX to support the development of the company's solid-state generator for potential use by the Department of the Air Force earlier this year.

FocisAI

Artificial intelligence startup FocisAI helps refinery owner-operators unlock actionable insights from 3D scans and images.

FocisAI was founded by CEO Tyler Wooten, COO Colin Snell and CTO Kyle Snell in 2026. It is a member of Greentown Labs and launched a seed round in September, which is expected to close by the end of the year, according to the company's application. It has rolled out 10 pilot programs and is looking to move into recurring, facility-scale deployments and scale its team in Houston this year.

Machine Saver Inc.

Industrial tech startup Machine Saver Inc. builds wireless and wired vibration and proximity sensors to tell heavy industry when a machine is about to fail. The company's technology runs on an 8-plus-year battery life and helps operators reduce downtime, improve maintenance and extend equipment life.

Machine Saver was founded by CEO Colton Bach and Quentin Bach in 2013. Its customers and partners include Houston Methodist, Blue Bell, Genemco, as well as energy and heavy industry, food and beverage, and cold chain companies, according to its application. The company is raising a Series A.

Square Robot

Energytech startup Square Robot develops and operates submersible inspection robotics that inspect aboveground storage tanks while they remain in service. The robots reduce downtime and costs, improve worker safety and limit hydrocarbon emissions.

Square Robot launched its Houston office in 2019 and closed a Series B in 2025. It plans to complete its first U.S. Navy demonstrator tank in November and is also developing real-time inspection software.

Venus Aerospace

Spacetech company Venus Aerospace is developing a high-thrust rotating detonation rocket engine (RDRE) that replaces the subsonic combustion used in conventional rocket engines. The RDRE is a compact, simpler engine that can deliver up to 15 percent greater efficiency for defense and space applications. It completed its first U.S. flight test of the engine last summer.

Venus Aerospace was founded in 2020 by CEO Cassie Duggleby and CTO Andrew Duggleby. It raised a $20 million Series A in 2022 and $42 million Series A2 in 2025. It closed a $91 million Series B earlier this year and expanded its leadership team. The company is working toward longer-duration and higher-thrust testing and advancing its flight program.